Ombitasvir/Paritaprevir/Ritonavir
- Generic Name
- Ombitasvir/Paritaprevir/Ritonavir
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
用于治疗成人基因1型慢性丙型肝炎，包括无肝硬化或伴代偿期肝硬化的患者。该治疗方案是全口服的、无干扰素、可联合或不联合利巴韦林。
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
- First Posted Date
- 2015-07-01
- Last Posted Date
- 2021-10-05
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 64
- Registration Number
- NCT02486406
- Locations
- 🇵🇷
San Jorge Children Hospital /ID# 136832, San Juan, Puerto Rico
🇺🇸Seattle Children's Hospital /ID# 137019, Seattle, Washington, United States
🇩🇪Helios Klinikum Wuppertal /ID# 142883, Wuppertal, Germany
Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-07-01
- Last Posted Date
- 2017-12-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 18
- Registration Number
- NCT02487199
Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-06-19
- Last Posted Date
- 2017-10-03
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 25
- Registration Number
- NCT02476617
A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-10-15
- Last Posted Date
- 2017-08-31
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 184
- Registration Number
- NCT02265237
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-08-19
- Last Posted Date
- 2021-07-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 60
- Registration Number
- NCT02219503
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-08-19
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 36
- Registration Number
- NCT02219477
A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) Infection
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2016-06-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 36
- Registration Number
- NCT02216422
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
- First Posted Date
- 2014-08-01
- Last Posted Date
- 2017-11-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 68
- Registration Number
- NCT02207088
A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-02-04
- Last Posted Date
- 2017-11-07
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 129
- Registration Number
- NCT01782495
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath